Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress
(Thomson Reuters ONE) -
Oslo, Norway, 23 August 2017: Targovax ASA ("Targovax" or "the Company"; OSE:
TRVX), a clinical stage company focused on developing immuno-oncology therapies
to target treatment-resistant solid tumors, today announces that three abstracts
been have accepted for poster presentation during the European Society for
Medical Oncology (ESMO) 2017 Congress to be held in Madrid, Spain from 8-12
September. The details of the abstracts can be found below.
Poster session: Poster Display session
Abstract title: TG01/GM-CSF and adjuvant gemcitabine in patients with resected
RAS-mutant adenocarcinoma of the pancreas
Poster number: 3568
Location: Hall 8
Time: 9 September, 13:15-14:15 CET
Poster session: Poster Display session
Abstract title: ONCOS-102 and pemetrexed/cisplatin in patients with unresectable
malignant pleural mesothelioma
Poster number: 3564
Location: Hall 8
Time: 9 September, 13:15-14:15 CET
Poster session: Poster Display session
Abstract title: An observational clinical study with RAS peptide vaccine TG01
evaluating immune response, safety and overall survival in patients with non-
resectable pancreatic cancer
Poster number: 1703
Location: Hall 8
Time: 10 September, 13:15-14:15 CET
All posters will be on display for the duration of the Congress and ESMO 2017 be
published online on the ESMO website at 00:05 CEST on Thursday, 31 August 2017.
In addition, the abstracts will also be published in the ESMO 2017 Congress
Abstract Book, a supplement to the official ESMO journal Annals of Oncology.
More information can be found on http://www.esmo.org/Conferences/ESMO-2017-
Congress.
--------------------------------------------------------------------------------
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli(at)targovax.com
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff(at)crux.no
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax(at)fticonsulting.com
About Targovax
Arming the patient's immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing
novel immuno-oncology therapies to target, primarily, treatment-resistant solid
tumors. Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
The Company's development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses as potential multi-target,
neo-antigen therapeutic cancer vaccines. ONCOS exclusively uses an adenovirus
that has been engineered to be an immune activator that selectively targets
cancer cells. In phase I studies it has demonstrated immune activation at
lesional level which was associated with clinical benefit. In an ongoing phase I
trial in advanced melanoma we expect important proof of concept data for
checkpoint inhibitor refractory patients.
The second, TG, is a target specific, neo-antigen therapeutic cancer vaccine
platform that solely targets tumors that express mutated forms of the RAS
protein. Mutations to this protein are common in many cancers and are known to
drive aggressive disease progression and treatment resistance. There is a high
unmet medical need for therapies that are effective against tumors that express
these mutations. The TG platform's therapeutic potential stems from its ability
to enable a patient's immune system to identify and then destroy tumors bearing
any RAS mutations. In early 2017, key proof of concept data for the TG platform
from a clinical trial of TG01 in resected pancreatic cancer patients showed
encouraging overall survival and will give guidance for the future clinical
development of this platform.
Targovax's development pipeline has three novel therapeutic candidates in
clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. Additionally, Targovax has other products in early stages of
development.
In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the
shares moved to Oslo Børs, the main Oslo Stock Exchange.
About ESMO 2017 Congress
The European Society for Medical Oncology (ESMO) is the leading professional
organisation for medical oncology. The ESMO 2017 Congress, in partnership with
the European Association for Cancer Research (EACR), will bring cancer
researchers and clinicians together to enable collaboration and the exchange of
ideas, from the laboratory to the bedside and back. This exciting partnership
creates a unique cancer congress in Europe with huge scientific reach and the
true potential to improve the lives of cancer patients. The ESMO Congress is the
most influential annual meeting for oncology professionals in Europe.
For more information, visit: http://www.esmo.org/.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Starcore Appoints New Chief Operating Officer
Datum: 23.08.2017 - 18:31 Uhr
Sprache: Deutsch
News-ID 557601
Anzahl Zeichen: 6316
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 474 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax ASA: Abstracts accepted for poster presentation at the ESMO 2017 Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
